COLUMBUS 5年更新:恩考拉非尼联合比美替尼对比维莫非尼或恩考拉非尼治疗BRAF V600突变黑色素瘤的随机开放标签III期试验
COLUMBUS试验5年更新显示,在577例BRAF V600突变晚期黑色素瘤患者中,恩考拉非尼联合比美替尼组5年无进展生存率和总生存率分别为23%和35%,高于维莫非尼组的10%和21%,且长期安全性可控。
要点
- 恩考拉非尼联合比美替尼组5年PFS率23%、OS率35%,维莫非尼组分别为10%、21%。
- 乳酸脱氢酶正常者中,联合组5年PFS率31%、OS率45%,维莫非尼组分别为12%、28%。
- 联合组中位缓解持续时间18.6个月,疾病控制率92.2%;维莫非尼组分别为12.3个月和81.2%。
核心结论
- 恩考拉非尼联合比美替尼在BRAF V600突变黑色素瘤患者中显示出持续的长期获益和一致的安全性特征。
研究设计与样本
- 随机、开放标签、III期试验,患者按1:1:1随机分配至恩考拉非尼450 mg每日一次联合比美替尼45 mg每日两次组、维莫非尼960 mg每日两次组或恩考拉非尼300 mg每日一次组。
- 共纳入577例局部晚期不可切除或转移性BRAF V600突变黑色素瘤患者,既往未治疗或一线免疫治疗后进展,其中联合组192例、维莫非尼组191例、恩考拉非尼组194例。
- 末例患者随机分组后65个月进行更新分析。
主要发现
- 联合组5年PFS率和OS率总体分别为23%和35%,乳酸脱氢酶正常者中分别为31%和45%。
- 维莫非尼组5年PFS率和OS率总体分别为10%和21%,乳酸脱氢酶正常者中分别为12%和28%。
- 联合组中位缓解持续时间为18.6个月,疾病控制率为92.2%;维莫非尼组中位缓解持续时间为12.3个月,疾病控制率为81.2%。
- 长期随访未发现新的安全性问题,结果与恩考拉非尼联合比美替尼已知的耐受性特征一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Combination treatment with BRAF and MEK inhibitors has demonstrated benefits on progression-free survival (PFS) and overall survival (OS) and is a standard of care for the treatment of advanced BRAF V600-mutant melanoma. Here, we report the 5-year update from the COLUMBUS trial (ClinicalTrials.gov identifier: NCT01909453). METHODS: Patients with locally advanced unresectable or metastatic BRAF V600-mutant melanoma, untreated or progressed after first-line immunotherapy, were randomly assigned 1:1:1 to encorafenib 450 mg once daily plus binimetinib 45 mg twice daily, vemurafenib 960 mg twice daily, or encorafenib 300 mg once daily. An updated analysis was conducted 65 months after the last patient was randomly assigned. RESULTS: Five hundred seventy-seven patients were randomly assigned: 192 to encorafenib plus binimetinib, 191 to vemurafenib, and 194 to encorafenib. The 5-year PFS and OS rates with encorafenib plus binimetinib were 23% and 35% overall and 31% and 45% in those with normal lactate dehydrogenase levels, respectively. In comparison, the 5-year PFS and OS rates with vemurafenib were 10% and 21% overall and 12% and 28% in those with normal lactate dehydrogenase levels, respectively. The median duration of response with encorafenib plus binimetinib was 18.6 months, with disease control achieved in 92.2% of patients. In comparison, the median duration of response with vemurafenib was 12.3 months, with disease control achieved in 81.2% of patients. Long-term follow-up showed no new safety concerns, and results were consistent with the known tolerability profile of encorafenib plus binimetinib. Interactive visualization of the data presented in this article is available at COLUMBUS dashboard. CONCLUSION: In this 5-year update of part 1 of the COLUMBUS trial, encorafenib plus binimetinib treatment demonstrated continued long-term benefits and a consistent safety profile in patients with BRAF V600-mutant melanoma.
引用
- Dummer R, Flaherty KT, Robert C, et al. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma. J Clin Oncol. 2022. PMID: 35862871. doi:10.1200/JCO.21.02659
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。